
PRIMA-1
CAS No. 5608-24-2
PRIMA-1( PRIMA 1 | PRIMA1 )
Catalog No. M15042 CAS No. 5608-24-2
A specific mutant p53 reactivator that induces apoptosis and enhances chemotherapeutic cytotoxicity in cancer cell lines.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 42 | In Stock |
![]() ![]() |
10MG | 60 | In Stock |
![]() ![]() |
25MG | 129 | In Stock |
![]() ![]() |
50MG | 195 | In Stock |
![]() ![]() |
100MG | 348 | In Stock |
![]() ![]() |
200MG | 518 | In Stock |
![]() ![]() |
500MG | 831 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NamePRIMA-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionA specific mutant p53 reactivator that induces apoptosis and enhances chemotherapeutic cytotoxicity in cancer cell lines.
-
DescriptionA specific mutant p53 reactivator that induces apoptosis and enhances chemotherapeutic cytotoxicity in cancer cell lines; is efficacious against myeloma cells with differential p53 genotypes, causes the demethylation of TP73, through DNMT1 depletion, to subsequently enhance UPR; selectively induces apoptosis and cell cycle arrest in p53 mutant cells compared to CAPAN-2 cells.Blood Cancer Phase 2 Clinical.
-
In VitroThe cell lines are cultured in the presence of PRIMA-1 (NSC-281668) at 0-140 μM. The IC50s are 35, 40, 50, 50, 60, 70 and 75 μM for PANC-1, HEC-1-B, SUM149, AN 3CA, Ishikawa, Panc02 and MDA-MB-231 cells, respectively.
-
In VivoPRIMA-1 (Prima-1) is a p53-modulating agent. 150 or 300 ppm PRIMA-1 significantly suppresses (P<0.0001) lung adenocarcinoma formation by 56% and 62%, respectively, after 17 weeks and 39% and 56%, respectively, after 34 weeks. Administration of 150 or 300 ppm PRIMA-1 significantly suppresses NNK-induced total lung adenocarcinoma formation by 57% or 62% (P<0.0001), respectively, after 17 weeks of exposure and by 39% or 56% (P<0.0001), respectively, after 34 weeks of exposure. As with administration of the lower (50 ppm) dose of CP-31398, administration of the lower (150 ppm) dose of PRIMA-1also slightly increases the number of NNK-induced lung adenomas.
-
SynonymsPRIMA 1 | PRIMA1
-
PathwayApoptosis
-
TargetMDM2-p53
-
Recptorp53
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number5608-24-2
-
Formula Weight185.2203
-
Molecular FormulaC9H15NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 44 mg/mL
-
SMILESO=C1C(CO)(CO)N2CCC1CC2
-
Chemical Name1-Azabicyclo[2.2.2]octan-3-one, 2,2-bis(hydroxymethyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Izetti P, et al. Invest New Drugs. 2014 Oct;32(5):783-94.
2. Bykov VJ, et al. Carcinogenesis. 2002 Dec;23(12):2011-8.
3. Teoh PJ, et al. Oncotarget. 2016 Sep 20;7(38):61806-61819.
molnova catalog



related products
-
STIMA 1
STIMA 1 is a small molecule mutant p53 reactivator that can stimulate mutant p53 DNA binding in vitro.
-
SP 141
SP 141 is a MDM2 inhibitor.SP-141 promotes MDM2 auto-ubiquitination and degradation, with anticancer activity.SP141, which bound directly to MDM2, promoting its auto-ubiquitination and degradation by the proteasome.
-
Pifithrin-β hydrobro...
A cyclic analog of Pifithrin-α and a small molecule inhibitor of p53; prevents dexamethasone-induced cell death in murine thymocytes with EC50 of 2.01 uM.